

Assessing brain immune activation in psychiatric disorders: clinical and preclinical PET imaging studies of the 18-kDa translocator protein

Thalia F. van der Doef^{1,2} · Janine Doorduyn³ · Bart N. M. van Berckel^{1,2} · Simon Cervenka⁴

Received: 22 July 2015 / Accepted: 26 August 2015 / Published online: 10 September 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract Accumulating evidence from different lines of research suggests an involvement of the immune system in the pathophysiology of several psychiatric disorders. During recent years, a series of positron emission tomography (PET) studies have been published using radioligands for the translocator protein (TSPO) to study microglia activation in schizophrenia, bipolar I disorder, major depression, autism spectrum disorder, and drug abuse. The results have been somewhat conflicting, which could be due to differences both in patient sample characteristics and in PET methods. In particular, further work is needed to address both methodological and biological sources of variability in TSPO levels, a process in which the use of animal models and small animal PET systems can be a valuable tool. Given this development, PET studies of immune activation have the potential to further increase our understanding of disease mechanisms in psychiatric disorders, which is a requisite in the search for new treatment approaches. Furthermore, molecular imaging could become an important clinical tool for identifying specific subgroups of patients or disease stages that would benefit from treatment targeting the immune system.

Keywords Psychiatry · PET · Neuroinflammation · Microglia · TSPO

The role of the immune system in psychiatric disorders

The concept that the immune system may have a role in the pathophysiology of psychiatric disorders has been discussed for several decades. Early observations in support of this hypothesis include reports of psychotic symptoms in autoimmune and infectious diseases engaging the central nervous system (CNS) [1, 2]. Furthermore, studies in both animals and humans show that immune activation can induce depressive-like symptoms, as part of what is commonly referred to as the “sickness behaviour” syndrome [3, 4].

With regard to studies in psychiatric populations, initial epidemiological observations of increased incidence rates of schizophrenia for cohorts born after influenza epidemics [5] have been followed up by a series of studies showing that infections during gestation or in early life lead to an increased risk of developing psychotic disorders [6]. In addition, autoimmune diseases and infections have been associated with mood disorders [7]. In support of a role for genetically determined alterations in the immune system in schizophrenia, a recent large-scale genome-wide association study found that associations were enriched for genes related to immune function [8]. Effects of genes related to immune function have also been found for depression, bipolar disorder, and autism [9, 10]. Furthermore, pharmacoepidemiological studies have suggested that anti-inflammatory drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), may lower the risk of psychiatric symptomatology [11].

✉ Simon Cervenka
simon.cervenka@ki.se

¹ Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands

² Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands

³ Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

⁴ Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden

Although the genetic and epidemiological data strongly suggest that immune function has a role in the development of psychiatric disease, an important question from a clinical perspective is if there are also ongoing brain immune disturbances in patients.

Post-mortem studies have shown increases in microglia in patients with schizophrenia [12, 13], autism [14], and cocaine abuse [15]. However, the post-mortem results may differ from the brain immune situation *in vivo* and in general there is a large delay between disease onset and post-mortem assessment. Studies on immune markers in blood, such as cytokines, have shown increased levels in both first-episode and chronic schizophrenia [16, 17] as well as in depression [18] and autism [19]. Similarly, gene expression of immune-related proteins has shown to be altered in schizophrenia and bipolar disorder [20]. However, findings have generally been inconsistent, with different markers showing effects in different studies, and there is often a large degree of overlap between patients and control subjects. Importantly, there is little direct passage of cytokines between brain and periphery [21, 22], and therefore, peripheral markers may not be representative of CNS processes. Studies in cerebrospinal fluid (CSF) are scarce, but alterations in immune markers have been shown for schizophrenia [23, 24], bipolar disorder [25, 26], and at least in a subgroup of patients with depression [27]. Although these studies are encouraging, a large degree of inconsistency still remains. Furthermore, CSF analyses cannot provide any anatomical information, and there is thus a need for more direct measures of brain immune activation in psychiatric patients.

Measuring brain immune function *in vivo*: molecular imaging of TSPO

Molecular imaging is currently the only method to directly examine brain biomarkers at a molecular level *in vivo*. Of the available tools, positron emission tomography (PET) is the most accurate method, whereas single-photon emission computed tomography (SPECT) has been less prevalent due to the lower sensitivity as well as limited temporal and spatial resolution as compared to PET [28]. Thus far, all PET studies assessing the immune system in psychiatric populations have targeted the 18-kDa translocator protein (TSPO), and this method is thus the focus of the present review.

TSPO, formerly known as the peripheral benzodiazepine receptor, is located in the outer mitochondrial membrane of microglia and, to some extent, astrocytes. Although its exact function remains unclear, TSPO has been described to be involved in many physiological processes, including cholesterol transport and steroid synthesis [29].

Importantly, microglia are considered to be the key cell type involved in CNS immune processes, as they can be activated by cytokines and additionally contribute further to cytokine release [30]. Activation of resident microglia and infiltration of macrophages contribute to neuronal injury and synaptic damage [29], although neurotrophic and protective functions have also been observed [31, 32]. TSPO is a widely used marker for immune activation in the CNS, since a change in phenotype and functional state of microglia is associated with increased TSPO expression [30].

The PET radioligand (*R*)-[¹¹C]PK11195 has been the most commonly used PET tracer to assess TSPO in the CNS. Several studies describe prolonged increased binding in patients with stroke and traumatic brain injury which can be seen as proof-of-concept studies [33, 34]. Since (*R*)-[¹¹C]PK11195 shows a high level of non-specific binding, during the last decade significant efforts have been made to develop new TSPO radioligands. Those that have hitherto been applied to psychiatric conditions are [¹¹C]DAA1106, [¹⁸F]FEPPA, and [¹¹C]PBR28 [35–40]. These second-generation ligands are considered to have improved signal-to-noise ratio compared to [¹¹C]PK11195, based on a 7- to 60-fold higher affinity for TSPO and animal blocking studies showing up to 80-fold higher specific binding than [¹¹C]PK11195 [36, 38, 40, 41]. A practical drawback with all these novel compounds is their sensitivity to a polymorphism in the gene encoding TSPO, which leads to three distinct binding classes: high-affinity binders (HABs; 49 % of the Western population), mixed-affinity binders (MABs; 42 %), and low-affinity binders (LABs; 9 %) [13, 42]. As a consequence, up to ten percentage of the population cannot be part of clinical studies due to LABs. In the remaining subjects, the effects of TSPO polymorphism require genotyping the subjects and controlling for genotype in the study design and analysis. Furthermore, second-generation TSPO radioligands have thus far not been validated in preclinical models to the same extent.

Psychiatric disorders and TSPO PET imaging: clinical studies

We identified all PET studies that examined TSPO binding in psychiatric disorders (Table 1). Thus far, schizophrenia is the most studied condition with four articles, whereas only one to two studies have been published for mood disorders, autism spectrum disorder, and drug abuse.

Schizophrenia

The first study on TSPO in schizophrenia used the radioligand (*R*)-[¹¹C]PK11195 in ten patients and ten age-

Table 1 Overview of clinical TSPO PET studies in psychiatric disorders

References	Disorder	Tracer	Controls/patients (number)	PET outcome measure	Main findings	Regions studied
Kenk et al. [46]	Schizophrenia	[¹⁸ F]FEPPA	27/16	2TCM V_T	No group differences	HIPP, TC, mPFC, DLPFC, striatum, CC, cingulum, PLIC, SLF
Takano et al. [45]	Schizophrenia	[¹¹ C]DAA1106	14/14	2TCM BP_{ND}^*	No group differences; correlations with symptom severity and disease duration	MTC, LTC, PC, OC, CER, striatum, ACC, PCC
Doorduyn et al. [44]	Schizophrenia	[¹¹ C]PK11195	8/7	2TCM BP_{ND}	Increase in hippocampus	HIPP, TC, FC, PC, OC, CER, basal ganglia, TH, midbrain, pons
van Berckel et al. [43]	Schizophrenia	[¹¹ C]PK11195	10/10	2TCM BP_P	Increase in total grey matter	Total grey matter
Setiawan et al. [53]	Major depression	[¹⁸ F]FEPPA	20/20	2TCM V_T	Increases in all regions; correlations with symptom severity	HIPP, TC, MPFC, DLPFC, VLPFC, FP, PC, OC, dPU, dCA, VST, ACC, TH, insula
Hannestad et al. [50]	Major depression	[¹¹ C]PBR28	10/10	1TCM, 2TCM, MA1 V_T	No group differences	TC, FC, PC, OC, CER, TH, CA, PU, white matter
Haarman et al. [55]	Bipolar I disorder	[¹¹ C]PK11195	11/14	2TCM BP_{ND}	Increase in right hippocampus	HIPP, TC, FC, DLPFC, PC, OC, CB, ACC, PCC, basal ganglia
Suzuki et al. [59]	Autism spectrum disorder	[¹¹ C]PK11195	20/20	SRTM BP_{ND} Ref: cerebellum**	Increase in all regions	STC, fusiform cortex, MFC, OFC, PC, CER, ACC, CC, brainstem
Narendran et al. [61]	Cocaine abuse	[¹¹ C]PBR28	17/15	2TCM V_T	No group differences	MTL, DLPFC, MPFC, OFC, CER, ACC, ST, midbrain
Sekine et al. [60]	Methamphetamine abuse	[¹¹ C]PK11195	12/12	SRTM BP_{ND} Ref: frontal, parietal, occipital cortex**	Increase in all regions	OC, insular cortex, TH, ST, midbrain

ITCM one-tissue compartment model, *2TCM* two-tissue compartment model, *MA1* multilinear analysis, *SRTM* simplified reference tissue model, BP_{ND} binding potential, V_T total distribution volume, *d* dorsal/dorso, *l* lateral, *m* medial, *o* orbito, *p* pre, *s* superior, *v* ventral/ventro, *ACC* anterior cingulate cortex, *CA* caudate, *CER* cerebellum, *CC* corpus callosum, *FC* frontal cortex, *FP* frontal pole, *HIPP* hippocampus, *OC* occipital cortex, *PC* parietal cortex, *PCC* posterior cingulate cortex, *PLIC* posterior limb of the internal capsule, *PU* putamen, *SLF* superior longitudinal fasciculus, *ST* striatum, *TH* thalamus, *TC* temporal cortex

* TSPO genotype was not accounted for

** Ref = reference tissue

matched healthy control subjects [43]. All patients were examined within 5 years of disease onset, with an average disease duration of 3.1 ± 1.7 years. (*R*)-[¹¹C]PK11195 binding potential (BP_P , as calculated with $K1 \cdot k3 / k2 \cdot k4$) values were calculated using a two-tissue compartment model (2TCM) with metabolite-corrected plasma as input function. Patients had mild symptoms at the time of PET scanning as measured with the Positive and Negative Syndrome Scale (PANSS), with average scores of 12 ± 3 and 14 ± 4 for symptoms, respectively, and they were all

on atypical antipsychotics. The authors observed an increase in (*R*)-[¹¹C]PK11195 binding potential in patients in total grey matter, which was the only region analysed (Table 1). No significant correlation between symptom severity and total grey matter BP_P was found.

Doorduyn et al. [44] used (*R*)-[¹¹C]PK11195 to examine seven patients with schizophrenia with active psychosis, defined by a score of 5 or more on 1 PANSS positive symptom item or a score of 4 on 2 items, in comparison with eight healthy volunteers. The disease duration ranged

from 1 to 16 years (average 5.3 ± 5.6 years), with 1–4 experienced psychotic episodes. Patients had moderate symptoms at the time of PET scanning, with average PANSS scores of 20 ± 3 , 17 ± 5 , and 37 ± 7 for positive, negative, and general subscales, respectively. All patients were using antipsychotics, and the use of benzodiazepines was allowed for 1–2 weeks prior to PET examinations. Substance use and anti-inflammatory drugs were reported as exclusion criteria. (*R*)-[¹¹C]PK11195 binding potential (BP_{ND} defined as k_3/k_4) was quantified using 2TCM. In contrast to the study by van Berckel et al. [43], the (*R*)-[¹¹C]PK11195 binding potential of whole-brain grey matter was not found to be increased in patients compared to control subjects. Multiple ROIs were examined (Table 1), and a significant increased BP_{ND} was found in the hippocampus of patients. To reduce the variation in the small sample size, the data were normalised to the whole-brain grey matter for statistical analysis which means that the results are not directly comparable to the other TSPO studies in schizophrenia.

Takano et al. [45] studied fourteen patients with chronic schizophrenia and fourteen age- and sex-matched controls with the second-generation tracer [¹¹C]DAA1106. Patients had a long disease duration (18.8 ± 12.2 years). All patients were on antipsychotics, and benzodiazepines were allowed for more than 1 month before the start of the study. Substance and alcohol abuse were exclusion criteria. All cortical grey matter regions were assessed, as well as the striatum, and BP_{ND} as quantified using 2TCM was the main outcome measure. Patients had moderate symptoms at the time of PET scanning as scored on PANSS (total score 78.6 ± 20.7). Although no significant differences in TSPO levels between patients and controls were reported, correlations were found between TSPO binding and disease duration as well as positive symptoms. However, TSPO genotype was not determined, and since in vitro studies show fourfold differences in [¹¹C]DAA1106 affinity between MAB and HAB subjects [42], this significantly limits the interpretation of the results.

Using [¹⁸F]FEPPA, Kenk et al. [46] examined grey matter frontal and temporal ROIs, striatum, and white matter ROIs in a sample of 16 patients (10 HABs and 6 MABs) and 27 controls (19 HABs and 8 MABs; Table 1). The disease duration was 14.8 ± 8.8 years, and patients had moderate symptoms at the time of PET scanning (PANSS total 70.2 ± 9.7). Patients were on treatment with either atypical or typical antipsychotics, and a minor proportion were also using antidepressants or anti-Parkinsonian drugs. Benzodiazepine use was not allowed except for clonazepam. Total distribution volumes (V_T) values were calculated using 2TCM with an arterial plasma input function. Since [¹⁸F]FEPPA binding is also sensitive to TSPO genotype, this factor was included in the statistical

analysis. No significant differences in V_T values were found between patients and controls in either white or grey matter regions.

Clinical factors that might influence the study results are patient characteristics such as disease duration, symptom severity, and medication use. Both the two (*R*)-[¹¹C]PK11195 studies that found an effect had patients with a shorter disease duration [43, 44], whereas no difference was reported in patients with a longer disease duration [46]. This could indicate that microglia activation has a more prominent role in early disease phases. However, in order to answer this question longitudinal studies are necessary, ideally including also measurements in first-episode patients and high-risk individuals. In addition, patients had mild to moderate symptoms at the time of PET scanning, and thus it is of interest to examine if more severe pathology shows a greater increase in TSPO binding. Importantly, benzodiazepine use was an exclusion criterion in all studies (except for clonazepam in one study [46]) since most benzodiazepines have affinity for the TSPO and can compete for binding with TSPO with the PET tracer [47]. However, a recent study found that this was mainly the case for the benzodiazepine diazepam in higher doses [48]. Further studies should be performed to confirm this observation, as alleviating this restriction could potentially improve recruitment of more severely ill patients.

One important limitation in all studies published thus far is that all patients were on treatment with antipsychotic drugs. Most antipsychotics, besides clozapine, tend to decrease TSPO expression [49]. Although evidence from in vivo human research is lacking, this suggests that there might be an underestimation of the signal. For instance, this could explain the negative findings in Kenk et al. [46]. Examination of drug-naïve patients will be critical to address this issue.

Mood disorders

To date, two studies assessed TSPO in patients with major depressive disorder and one study examined bipolar I patients (Table 1).

In the study by Hannestad et al. [50], [¹¹C]PBR28 was used to examine ten patients with major depression (MD) and ten healthy controls. The sample included seven HABs in both the patient group and control group, respectively. Patients were allowed to take antidepressant medications if the dose had been stable for at least 4 weeks (although it was not reported how many patients were administered antidepressants at the time of PET). Laboratory signs of peripheral immune activation, as defined by elevated high-sensitive C-reactive protein (CRP), were an exclusion criterion. Symptom severity at the time of examination was

mild to moderate, with 19.7 ± 6.7 scores on the Montgomery–Åsberg Depression Rating Scale (MADRS, range 0–60; 0–6 normal, 7–19 mild, 20–34 moderate, >34 severe depression [51]). This represented a significant reduction from 25.6 ± 7.5 at screening. Groups were matched for TSPO genotype. [^{11}C]PBR28 V_T values were calculated using 1TCM, 2TCM, and the multilinear analysis MA1 [52], using the metabolite-corrected arterial plasma curve as input function. In addition, V_T corrected for plasma free fraction (V_T/f_p) was determined. No significant differences in binding were found in a selection of cortical ROIs, white matter, and basal ganglia. Using V_T/f_p instead of V_T did not change these results.

Setiawan et al. [53] examined twenty MD patients (15 HABs, 5 MABs) and twenty healthy controls (14 HABs and 6 MABs) using [^{18}F]FEPPA. All patients were medication-free for at least 6 weeks prior to the PET examination. Depressive symptoms were moderate to severe, with average scores of 20 ± 3.8 on the 17-item Hamilton Depression Rating Scale (HDRS, range 0–52; 0–7 normal, 8–13 mild, 14–18 moderate, 19–22 severe, ≥ 23 very severe depression [54]). [^{18}F]FEPPA V_T calculated using 2TCM was the main outcome measure, and ROIs selected were prefrontal cortex, anterior cingulate cortex (ACC), and insula. Genotype was included as a factor in the statistical analysis. A global effect of diagnosis on [^{18}F]FEPPA V_T was shown, with higher values in patients in all regions examined. Furthermore, HDRS scores were positively correlated with TSPO V_T in the ACC, after correcting for genotype. Serum markers for neuroinflammation were measured, but there were no correlations with brain TSPO levels.

Haarman et al. [55] studied fourteen bipolar I patients compared to eleven healthy volunteers. All patients except one were euthymic, and the disease duration ranged from 2 to 37 years (average 25.6 ± 12.0 years). All patients had experienced multiple depressive and hypomanic or manic episodes. All except one patient were on mood-stabilising medication. (R)-[^{11}C]PK11195 BP_{ND} was quantified using 2TCM with plasma input function. Multiple brain regions were analysed, although hippocampus was selected as the main ROI, based on human and preclinical evidence suggesting that this region could be a particular focus of microglia activation. For the statistical analysis, binding in whole-brain grey matter was used as a covariate to reduce the between-subject variation. Whereas BP_{ND} in the whole-brain was not different between patients and healthy volunteers, higher values were observed in the right hippocampus of bipolar I patients.

The differences in clinical factors between the mood disorder studies make it difficult to compare the PET outcome. In the two studies on depression, the study of Setiawan et al. [53] had a significantly larger sample size, and patients had more severe symptoms than in the study of

Hannestad et al. [50], which might explain the difference in results. A further difference is the exclusion of signs of mild peripheral immune activation in the latter study. Since CRP has shown to be elevated in patients in depression [56], suggesting that peripheral immune activation is related to the disease mechanism, this could have led to a selection bias towards patients with relatively low levels of immune activation.

Furthermore, in two of the studies the patients were on treatment with mood-stabilising medication [50, 55], whereas in the study by Setiawan [53], patients were medication-free for 6 weeks. Most mood-stabilising medications tend to decrease TSPO expression [57, 58], which suggests an underestimation of the signal in the patients who were assigned to treatment, although this has to be confirmed in future studies with medication-naïve patients.

Developmental disorders

To date, only one PET study has assessed TSPO binding in patients with developmental disorders. In the study by Suzuki et al. [59], (R)-[^{11}C]PK11195 was used to examine twenty individuals with autism spectrum disorder and twenty age- and intelligence quotient (IQ)-matched controls. Patients were young adults in an age range from 18.6 to 31.9 (average 23.3 ± 4.0) years, had IQ scores above 80 (average 95.9 ± 16.7), and did not receive any medication. Arterial blood was not sampled; instead, (R)-[^{11}C]PK11195 BP_{ND} was quantified using a reference tissue approach. A normalised input curve based on the averaged TACs from the ROIs placed over the cerebellar cortices in the control group was used for both the control and the patient data analysis. In the ROI-based analysis, an overall statistical effect was shown, and increased (R)-[^{11}C]PK11195 binding potential was reported in all examined regions, including (subparts of) the cerebellum, ACC, corpus callosum, and frontal, temporal, and parietal cortex (Table 1). These results were confirmed in a voxel-based analysis. There were no correlations between TSPO BP_{ND} and clinical symptoms levels. As discussed below, the reference tissue approach used in the study limits the conclusions that can be drawn.

Substance use disorders and the potential confound of drug use

Two PET studies examined TSPO in substance use disorders (Table 1). Sekine et al. [60] used (R)-[^{11}C]PK11195 to examine twelve methamphetamine abusers in comparison with twelve healthy volunteers. The disease duration of the patients ranged from 1 to 12 years (average 6.8 ± 3.9 years); however, patients were abstinent on average almost 2 years prior to PET examinations. A

modified version of the Drug Effect Rating Scale was used to assess the scale for methamphetamine craving. Scores were in a range from 1 (no craving) to 10 (most intense craving) with an average score of 4.9 ± 3.4 . PET data were analysed with a reference tissue approach, whereby averaged TACs from the frontal, parietal, and occipital cortices from the control group were used for both the control and the patient data analysis. Significantly higher BP_{ND} values were found in methamphetamine abusers in all ROIs studied, with differences ranging from 3- to 15-fold. A significant negative correlation was found between (*R*)- $[^{11}C]PK11195 BP_{ND}$ and the duration of methamphetamine abstinence in midbrain, thalamus, and striatum, suggesting that microglial function can be normalised by protracted abstinence.

In the study by Narendran et al. [61], 15 chronic cocaine abusers (8 HABs, 5 MABs, 2 LABs) and seventeen healthy controls (12 HABs, 4 MABs, 1 LAB) were examined using $[^{11}C]PBR28$. Patients were on average 39.9 ± 9.0 years old and had been smoking crack cocaine for an average of 17 ± 7 years. Patients had a minimum of 2 weeks outpatient abstinence as monitored with urine toxicology and did not receive medication. V_T values were calculated in a standard manner, using 2TCM with an arterial plasma input function, and data were corrected for TSPO genotype. No differences in $[^{11}C]PBR28 V_T$ were observed between patients and control subjects, as assessed in both cortical and subcortical brain regions.

Thus, these two studies differ markedly in their findings. However, apart from the fact that different drugs of abuse were studied, a direct comparison is precluded since there are major differences in both the clinical status of patients, such as time of abstinence, and methodology—in particular, the use of a reference region in the study by Sekine et al. (see below for discussion).

For most psychiatric patients groups, there is an increased prevalence of substance use disorders, such as alcohol, cannabis, and nicotine use [62]. For instance, cannabis is considered to be the most commonly used illegal drug of abuse among patients with bipolar disorder and schizophrenia [63, 64]. Although substance use disorder was an exclusion criterion in all studies, it cannot be excluded that patients had a higher recreational use of drugs of abuse. In most studies, actual drug use was assessed with urine analysis [43, 46, 50, 53, 60, 61]. However, only four of the studies reported on or controlled for smoking status, of which one study included only non-smokers [53], one study reported only three smokers in the patient group [50], one study allowed smoking and matched patients and controls for nicotine smoking status [61], and one study did not include subjects that fulfilled nicotine-related DSM-IV criteria [60]. Importantly, *in vitro* studies have shown that cannabinoids and nicotine have a

suppressant effect on the immune system [65, 66]. Although these observations remain to be confirmed *in vivo*, the use of these common drugs of abuse could thus theoretically diminish differences in TSPO levels between patients and control subjects, which might in some cases contribute to negative findings. In contrast, if an effect of psychostimulants in TSPO levels even after long abstinence intervals can be confirmed, group differences in the use of this drug could confound the results in the other direction.

Preclinical studies of TSPO and psychiatric disorders


Animal models and microglia activation

As psychiatric disorders are complex human disorders of which the aetiology and the exact pathophysiology are unknown, the three criteria commonly used for the validation of an animal model, i.e. face, construct, and predictive validity [67], cannot be fulfilled by a single animal model. Animal models of psychiatric disorders do therefore only manifest certain aspects that can be translated to the human disease, i.e. endophenotypes, such as hyperlocomotion, anxiety, or deficits in prepulse inhibition. With regard to the role of the immune systems in psychiatric disorders, many animal models have linked psychotic- and depressive-like behaviour to inflammatory processes. For instance, modelling effects of maternal immune activation on the risk of developing schizophrenia, viral infection of pregnant dams resulted in psychotic-like symptoms in the offspring, and also microglia were found to be activated [68, 69]. The bacterial endotoxin lipopolysaccharide (LPS) is often used to induce depressive-like behaviour in rodents, leading to immediate sickness behaviour followed by behavioural deficits that can be linked to depression [70, 71]. Importantly, LPS has been shown to induce an activation of microglia, lasting several days, as detected using immunohistochemistry [72]. Conversely, animal models for stress-induced depression have shown to induce both depressive behaviour and microglia activation [73].

Preclinical TSPO PET imaging

With the advent of small animal PET systems, it has become feasible to estimate TSPO levels in rats and mice, thus enabling a translational approach (Fig. 1). Thus far, only a few studies have assessed TSPO in animal models of psychiatric disorders. Herpes virus-induced psychotic-like behaviour in rats was found to be accompanied by microglia activation, as shown with (*R*)- $[^{11}C]PK11195$ PET [74].

Fig. 1 Cross-species TSPO imaging using [^{11}C]PBR28: SUV images of **a** mouse **b** rat, and **c** a healthy human subject. All PET images are overlaid over MR images. Courtesy of the PET centre, Karolinska Institutet



(*R*)-[^{11}C]PK11195 uptake was found to increase with the increased severity of psychotic-like behaviour, and psychotic-like behaviour and microglia activation could be reduced by antipsychotic treatment. Dobos et al. [75] used (*R*)-[^{11}C]PK11195 PET to show microglia activation and depressive-like behaviour following intracerebral LPS injection in mice. Recently, LPS-induced systemic inflammation in baboons was shown to induce an activation of microglia, as shown with [^{11}C]PBR28 PET [76]. A robust increase in TSPO binding was observed at 1 and 4 h after intravenous injection of LPS. Depressive-like behaviour was not assessed in this study.

Methodological considerations

Taken together, the data thus far suggest a modest elevation of TSPO in psychiatric disorders. In general, the increase was found throughout the entire brain, although some studies reported a more focal elevation. However, almost half of the studies did not find a difference between

patients and control subjects. Importantly, the results of the TSPO PET studies are in many instances difficult to compare, not only due to differences in patient characteristics as discussed above, but also since the methods differ in many aspects. In the following, we discuss some key methodological points of relevance for interpreting the findings.

The gold standard for TSPO PET quantification is to apply a 2TCM, using a metabolite-corrected plasma input function to estimate the contribution of free and non-specific binding to the brain signal. The outcome parameter of choice using this approach is V_T , since the direct estimation of BP, for instance, by calculating k_3/k_4 is less reliable. Therefore, to facilitate comparisons between the studies, it would have been useful if the studies with BP as outcome parameter had additionally reported V_T values.

Plasma input models are considered to have a high variability, which may be due to methodological issues in measuring the metabolite-corrected plasma input curve. In order to reduce variability of plasma input models, several approaches have been proposed.

In two of the studies reviewed above, normalisation of regional values to whole-brain binding was performed [44, 55]. Although this reduces the variance, the drawback with this approach is that it may underestimate true specific binding, especially in case of a global increase. Furthermore, the whole cortex cannot be analysed using this approach.

Reference tissue approaches, such as simplified reference tissue method (SRTM) [77] and Logan DVR [78], are in general preferred above plasma input models if a reference region can be identified, both to reduce noise as well as from a practical perspective since arterial sampling can then be eliminated. This may be particularly important for psychiatric patient groups. One method is to use ratios of standardised uptake values, which was recently reported to be more sensitive than V_T to detect TSPO elevations in Alzheimer's disease for [^{11}C]PBR28, with cerebellum as reference region [79]. However, the use of this method assumes a very focal TSPO elevation, which might not be the case for most psychiatric disorders, and is sensitive to bias induced by difference in blood flow between regions and between groups.

In general, all reference tissue approaches are problematic in TSPO PET studies as there is no anatomical region in the brain devoid of TSPO. Whereas this protein was initially not thought to be present in the non-diseased brain, widespread (R)-[^{11}C]PK11195 BP_{ND} increase was found in healthy ageing [80]. In addition, specific binding to TSPO in healthy individuals was recently confirmed in a TSPO blocking study [81]. In the studies on autism and methamphetamine use by Suzuki et al. [59] and Sekine et al. [60], normalised average time activity curves (TACs) from the control group were used for both patient and control data, which is not according to convention for reference tissue approaches and creates further problems. In this case, group differences in radioligand delivery and non-displaceable binding are not taken into account, which might generate artificially high BP_{ND} values in patients, and the results therefore have to be interpreted with caution.

An alternative approach to identifying a reference “region” is to identify voxels with low specific binding based on the shape of the TAC using supervised cluster analysis. Several methods have been published for this purpose, and they show reliable results in normal ageing and after traumatic brain injury, both conditions leading to robust microglia activation [80, 82]. However, the validity of voxels devoid of TSPO can be questioned as for anatomical reference regions, and this method might underestimate the signal in comparison with other approaches [83]. Another method to eliminate the need for arterial blood sampling is to use an image derived input function, by extracting time-activity curves from PET voxels corresponding to blood vessels. This approach has been validated for tracers such as [^{11}C] flumazenil and [^{11}C] AZ10419369 [84], and

preliminary data has shown feasibility for this method to quantify [^{11}C]PBR28 using HRRT [85]. So far, neither of these approaches have been used to study psychiatric populations.

General comments and future directions

It is well established that immune activation generally has a negative effect on psychological well-being and may contribute to both psychotic and depressive symptoms. A role for immune-related processes as part of specific, causative disease mechanisms in psychiatric disorders is at present more uncertain. For schizophrenia and autism, both genetic and epidemiological associations to immune function could reflect a role for immunological factors affecting neurodevelopment, which, for instance, is in line with recent observations suggesting that microglia are involved in synaptic pruning as well as providing trophic support for neuronal growth [32]. An alternative interpretation of these early effects is the “sensitisation” theory, postulating that early immune challenges to a genetically vulnerable system lead to an increased inflammatory response later in life [86]. Even so, the changes in psychiatric disorders are likely to be more subtle than for classic CNS autoimmune disorders such as multiple sclerosis (MS) and systemic lupus erythematosus (SLE), as there are no radiological signs and the changes in CSF and blood are less distinct. Since the immune system can in certain instances even be regarded as neuroprotective [31], immune dysregulation in psychiatric disorders may even be conceived as an imbalance rather than a “one-dimensional” immune response.

Given these proposed more subtle immune changes in psychiatric disorders, a major challenge for clinical TSPO PET studies is the large degree of variability even in healthy individuals. This is true irrespective of the radioligand and methods of quantification used. In the studies reviewed above, where variability was reported, the overall % covariance (COV) was around 35 % for second-generation radioligands across genotypes, and 25 % for (R)-[^{11}C]PK11195. With regard to interindividual variability, this has shown to be moderate to high for both (R)-[^{11}C]PK11195 [87] and [^{11}C]PBR28 [88, 89], whereas reproducibility has not been assessed for any other TSPO radioligands. Although part of this variability may be due to methodological noise as discussed above, there may also be biological explanations. For instance, in Collste et al. [89] diurnal effects were shown on GM V_T values, indicating that part of the variability could be due to natural fluctuations in the immune system in health. The variability in TSPO levels has important implications in terms of the sample samples needed, both for group comparisons and for longitudinal studies. For instance, in the study on

schizophrenia by Kenk et al. [46] based on mean and variability of VT values, it was calculated that 21 subjects per group was required to detect a 20 % difference ($\alpha = 0.05$ and power = 0.8), which can be compared to the 16 % increase in [^3H]PBR28 shown in a post-mortem study [13]. If similar effects are expected in other disorders, most studies performed thus far may have been underpowered. Sample size may be particularly critical for studies using second-generation radioligands, since accounting for TSPO genotype in the analysis reduces statistical degrees of freedom. To enhance the sensitivity of TSPO PET, an important direction of research will be not only to reduce methodological noise by finding reliable alternatives to arterial sampling, but also to identify the physiological factors that may influence TSPO levels in brain.

One important limitation for PET TSPO studies in general is the lack of specificity of this marker. For instance, TSPO is present also in astrocytes, which could contribute to the signal [90, 91], and although both cell types contribute to immune response, the specific type of cell may have implications in terms of treatment. Furthermore, for the microglia population, TSPO cannot distinguish between pro-inflammatory (M1) and protective (M2) subpopulations. Thus, it will also be crucial to developing tracers for other, more specific microglia markers that are also sensitive to the functional phenotype. Importantly, PET data then need to be combined with other measures of immune function in order to fully reflect the immunological status for each disease condition. Although TSPO levels were compared to serum markers of inflammation in some studies reviewed above, ideally this comparison should be done using CFS samples which more closely reflect the state of the CNS immune system.

A crucial aim for research on the immune system in psychiatry is to inform new treatment strategies. In schizophrenia, depression, and autism, randomised controlled studies have shown that the addition of cyclooxygenase (COX)-2 inhibitors to antipsychotics and antidepressants treatment may lead to amelioration of symptoms [92–94], although negative results have also been reported [95]. In psychosis, both the COX inhibitor aspirin and the broad-spectrum tetracycline antibiotic minocycline, which directly attenuates microglia activation, have shown to reduce symptoms [96, 97]. However, the immune hypothesis of psychiatric disorders would implicate a need for drugs specifically directed towards causative mechanisms. Molecular imaging is an important tool towards this goal, as it allows for non-invasive studies in both patients and animal models. Thus, immune markers can be followed over time, allowing for monitoring of disease progress and treatment effect. For instance, [^{11}C]PBR28 PET was recently used to detect effects of immune-targeted treatment in Parkinson's disease [98].

Furthermore, due to the translational nature of PET, clinical studies can be supported by preclinical experiments, also allowing for validation with post-mortem techniques such as immunohistochemistry. For many psychiatric disorders where large clinical trials have suffered from negative findings, these approaches could be critical towards revitalising drug development programmes.

With increasing understanding of the biological processes as well as methodological refinement, PET studies of the immune system promise to be an important tool also for clinical use. An important task will be to aid diagnosis and potentially identify specific subgroups of psychiatric patients in need of immune-targeting treatment. For instance, a proportion of patients with schizophrenia show auto-antibodies for neural receptors, suggesting that these patients may constitute a subgroup in specific need of treatment targeted against the immune system [99]. In depression, specific subgroups of patients were shown to respond to anti-TNF treatment [100]. Importantly, such PET markers may prove to be specific for particular pathophysiological mechanisms and symptom dimensions, rather than reflecting current disease classifications according to DSM.

Acknowledgments The contributions of S. Cervenka and B.N.M. van Berckel were supported by European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no HEALTH-F2-2011-278850 (INMIND).

Author contributions T.F. van der Doef involved in Literature search and Review, Content Planning, Writing, Editing. J. Doorduyn involved in Literature search and Review, Content Planning, Writing, Editing. B.N.M. van Berckel involved in Literature search and Review, Content Planning, Writing, Editing. S. Cervenka involved in Literature search and Review, Content Planning, Writing, Editing.

Compliance with ethical standards

Conflict of interest TF. van der Doef, J. Doorduyn, B.N.M. van Berckel, and S. Cervenka have nothing to disclose.

Human and animal rights statement This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

References

1. Oommen KJ, Johnson PC, Ray CG (1982) Herpes simplex type 2 virus encephalitis presenting as psychosis. *Am J Med* 73:445–448

2. Felgenhauer K (1990) Psychiatric disorders in the encephalitic form of multiple sclerosis. *J Neurol* 237:11–18
3. Reichenberg A, Yirmiya R, Schuld A et al (2001) Cytokine-associated emotional and cognitive disturbances in humans. *Arch Gen Psychiatry* 58:445–452
4. Dantzer R, O'Connor JC, Freund GG et al (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* 9:46–56
5. Mednick SA, Machon RA, Huttunen MO, Bonnet D (1988) Adult schizophrenia following prenatal exposure to an influenza epidemic. *Arch Gen Psychiatry* 45:189
6. Arias I, Sorlozano A, Villegas E et al (2012) Infectious agents associated with schizophrenia: a meta-analysis. *Schizophr Res* 136:128–136
7. Benros ME, Waltoft BL, Nordentoft M et al (2013) Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. *JAMA Psychiatry* 70:812–820
8. Ripke S, Neale BM, Corvin A et al (2014) Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 511:421–427
9. Odell D, Maciulis A, Cutler A et al (2005) Confirmation of the association of the C4B null allele in autism. *Hum Immunol* 66:140–145
10. Consortium N and PAS of PG (2015) Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. *Nat Neurosci* 18:199–209
11. Laan W, Selten J-P, Grobbee DE et al (2007) Non-steroidal anti-inflammatory drugs and the risk of psychosis. *Eur Neuropsychopharmacol* 17:309–311
12. Radewicz K, Garey LJ, Gentleman SM, Reynolds R (2000) Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. *J Neuropathol Exp Neurol* 59:137–150
13. Kreisl WC, Jenko KJ, Hines CS et al (2013) A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. *J Cereb Blood Flow Metab* 33:53–58
14. Morgan JT, Chana G, Pardo CA et al (2010) Microglial activation and increased microglial density observed in the dorso-lateral prefrontal cortex in autism. *Biol Psychiatry* 68:368–376
15. Little KY, Ramssen E, Welchko R et al (2009) Decreased brain dopamine cell numbers in human cocaine users. *Psychiatry Res* 168:173–180
16. Uptegrove R, Manzanares-Teson N, Barnes NM (2014) Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. *Schizophr Res* 155:101–108
17. Miller BJ, Buckley P, Seabolt W et al (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. *Biol Psychiatry* 70:663–671
18. Dowlati Y, Herrmann N, Swardfager W et al (2010) A meta-analysis of cytokines in major depression. *Biol Psychiatry* 67:446–457
19. Mitchell RHB, Goldstein BI (2014) Inflammation in children and adolescents with neuropsychiatric disorders: a systematic review. *J Am Acad Child Adolesc Psychiatry* 53:274–296
20. Drexhage RC, van der Heul-Nieuwenhuijsen L, Padmos RC et al (2010) Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturally treated patients. *Int J Neuropsychopharmacol* 13:1369–1381
21. Bromander S, Anckarsäter R, Kristiansson M et al (2012) Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study. *J Neuroinflammation* 9:242
22. Maier B, Laurer H-L, Rose S et al (2005) Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. *J Neurotrauma* 22:822–835
23. Soderlund J, Schroder J, Nordin C et al (2009) Activation of brain interleukin-1beta in schizophrenia. *Mol Psychiatry* 14:1069–1071
24. Schwieler L, Larsson MK, Skogh E et al (2014) Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia—significance for activation of the kynurenine pathway. *J Psychiatry Neurosci* 39:140126
25. Jakobsson J, Bjerke M, Sahebi S et al (2015) Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. *J Psychiatry Neurosci* 40:250–258
26. Söderlund J, Olsson SK, Samuelsson M et al (2011) Elevation of cerebrospinal fluid interleukin-1β in bipolar disorder. *J Psychiatry Neurosci* 36:114–118
27. Young JJ, Bruno D, Pomara N (2014) A review of the relationship between proinflammatory cytokines and major depressive disorder. *J Affect Disord* 169C:15–20
28. Rahmim A, Zaidi H (2008) PET versus SPECT: strengths, limitations and challenges. *Nucl Med Commun* 29:193–207
29. Liu G-J, Middleton RJ, Hatty CR et al (2014) The 18 kDa translocator protein, microglia and neuroinflammation. *Brain Pathol* 24:631–653
30. Venetti S, Lopresti BJ, Wiley CA (2013) Molecular imaging of microglia/macrophages in the brain. *Glia* 61:10–23
31. Hohlfeld R, Kerschensteiner M, Mehl E (2007) Dual role of inflammation in CNS disease. *Neurology* 68:S58–S63 (**discussion S91–6**)
32. Paolicelli RC, Gross CT (2011) Microglia in development: linking brain wiring to brain environment. *Neuron Glia Biol* 7:77–83
33. Cagnin A, Gerhard A, Banati RB (2002) In vivo imaging of neuroinflammation. *Eur Neuropsychopharmacol* 12:581–586
34. Gerhard A, Schwarz J, Myers R et al (2005) Evolution of microglial activation in patients after ischemic stroke: a [¹¹C](R)-PK11195 PET study. *Neuroimage* 24:591–595
35. Fujita M, Imaizumi M, Zoghbi S, Fujimura Y (2008) Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for. *Neuroimage* 40:43–52
36. Imaizumi M, Briard E, Zoghbi S, Gourley J (2008) Brain and whole-body imaging in nonhuman primates of PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. *Neuroimage* 39:1289–1298
37. Ikoma Y, Yasuno F, Ito H et al (2007) Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [(11)C]DAA1106. *J Cereb Blood Flow Metab* 27:173–184
38. Maeda J, Suhara T, Zhang M-R et al (2004) Novel peripheral benzodiazepine receptor ligand [¹¹C]DAA1106 for PET: an imaging tool for glial cells in the brain. *Synapse* 52:283–291
39. Rusjan PM, Wilson AA, Bloomfield PM et al (2011) Quantitation of translocator protein binding in human brain with the novel radioligand [¹⁸F]-FEPPA and positron emission tomography. *J Cereb Blood Flow Metab* 31:1807–1816
40. Wilson AA, Garcia A, Parkes J et al (2008) Radiosynthesis and initial evaluation of [¹⁸F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. *Nucl Med Biol* 35:305–314
41. Kreisl WC, Fujita M, Fujimura Y et al (2010) Comparison of [(11)C](R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker. *Neuroimage* 49:2924–2932

42. Owen DRJ, Gunn RN, Rabiner EA et al (2011) Mixed-affinity binding in humans with 18-kDa translocator protein ligands. *J Nucl Med* 52:24–32
43. Van Berckel BN, Bossong MG, Boellaard R et al (2008) Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. *Biol Psychiatry* 64:820–822
44. Doorduyn J, de Vries EFJ, Willemsen ATM et al (2009) Neuroinflammation in schizophrenia-related psychosis: a PET study. *J Nucl Med* 50:1801–1807
45. Takano A, Arakawa R, Ito H et al (2010) Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. *Int J Neuropsychopharmacol* 13:943–950
46. Kenk M, Selvanathan T, Rao N et al (2014) Imaging neuroinflammation in gray and white matter in schizophrenia: an in vivo PET study with [18F]-FEPPA. *Schizophr Bull* 41:85–93
47. Gavish M, Bachman I, Shoukrun R et al (1999) Enigma of the peripheral benzodiazepine receptor. *Pharmacol Rev* 51:629–650
48. Kalk NJ, Owen DR, Tyacke RJ et al (2013) Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET studies? *Synapse* 67:909–912
49. Danovich L, Veenman L, Leschiner S et al (2008) The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production. *Eur Neuropsychopharmacol* 18:24–33
50. Hannestad J, Della Gioia N, Gallezot JD et al (2013) The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [11C]PBR28 PET study. *Brain Behav Immun* 33:131–138
51. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. *Br J Psychiatry* 134:382–389
52. Ichise M, Toyama H, Innis RB et al (2002) Strategies to improve neuroreceptor parameter estimation by linear regression analysis. *J Cereb Blood Flow Metab* 22:1271–1281
53. Setiawan E, Wilson AA, Mizrahi R et al (2015) Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. *JAMA Psychiatry* 72:268–275
54. Hamilton M (1960) A rating scale for depression. *J Neurol Neurosurg Psychiatry* 23:56–62
55. Haarman BCMB, Riemersma-Van der Lek RF, de Groot JC et al (2014) Neuroinflammation in bipolar disorder: a [11C]-(R)-PK11195 positron emission tomography study. *Brain Behav Immun* 40:219–225
56. Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. *Psychosom Med* 71:171–186
57. Haarman BBCM, Riemersma-Van der Lek RF, Burger H et al (2014) Relationship between clinical features and inflammation-related monocyte gene expression in bipolar disorder—towards a better understanding of psychoimmunological interactions. *Bipolar Disord* 16:137–150
58. Rybakowski JK (2000) Antiviral and immunomodulatory effect of lithium. *Pharmacopsychiatry* 33:159–164
59. Suzuki K, Sugihara G, Ouchi Y et al (2013) Microglial activation in young adults with autism spectrum disorder. *JAMA Psychiatry* 70:49–58
60. Sekine Y, Ouchi Y, Sugihara G et al (2008) Methamphetamine causes microglial activation in the brains of human abusers. *J Neurosci* 28:5756–5761
61. Narendran R, Lopresti BJ, Mason NS et al (2014) Cocaine abuse in humans is not associated with increased microglial activation: an 18-kDa translocator protein positron emission tomography imaging study with [11C]PBR28. *J Neurosci* 34:9945–9950
62. Ziedonis D, Hitsman B, Beckham JC et al (2008) Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. *Nicotine Tob Res* 10:1691–1715
63. Bally N, Zullino D, Aubry JM (2014) Cannabis use and first manic episode. *J Affect Disord* 165:103–108
64. Leweke FM, Koethe D (2008) Cannabis and psychiatric disorders: it is not only addiction. *Addict Biol* 13:264–275
65. Guan Y-Z, Jin X-D, Guan L-X et al (2014) Nicotine inhibits microglial proliferation and is neuroprotective in global ischemia rats. *Mol Neurobiol* 51:1480–1488
66. Suárez-Pinilla P, López-Gil J, Crespo-Facorro B (2014) Immune system: a possible nexus between cannabinoids and psychosis. *Brain Behav Immun* 40:269–282
67. Van der Staay FJ, Arndt SS, Nordquist RE (2009) Evaluation of animal models of neurobehavioral disorders. *Behav Brain Funct* 5:11
68. Mattei D, Djodari-Irani A, Hadar R et al (2014) Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia. *Brain Behav Immun* 38:175–184
69. Juckel G, Manitz MP, Brüne M et al (2011) Microglial activation in a neuroinflammatory animal model of schizophrenia: a pilot study. *Schizophr Res* 131:96–100
70. Fu X, Zunich SM, O'Connor JC et al (2010) Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. *J Neuroinflammation* 7:43
71. O'Connor JC, Lawson MA, André C et al (2009) Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. *Mol Psychiatry* 14:511–522
72. Buttini M, Limonta S, Boddeke HWGM (1996) Peripheral administration of lipopolysaccharide induces activation of microglial cells in rat brain. *Neurochem Int* 29:25–35
73. Reader BF, Jarrett BL, McKim DB et al (2015) Peripheral and central effects of repeated social defeat stress: monocyte trafficking, microglial activation, and anxiety. *Neuroscience* 289:429–442
74. Doorduyn J, Klein HC, Dierckx RAJO, de Vries EFJ (2010) HSV-1 induced behavioural changes and microglia cell activation are inhibited by antipsychotics. *Eur J Nucl Med Mol Imaging* 37:S387
75. Dobos N, De Vries EFJ, Kema IP et al (2012) The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. *J Alzheimer's Dis* 28:905–915
76. Hannestad J, Gallezot JD, Schafbauer T et al (2012) Endotoxin-induced systemic inflammation activates microglia: [11C]PBR28 positron emission tomography in nonhuman primates. *Neuroimage* 63:232–239
77. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. *Neuroimage* 4:153–158
78. Logan J (2000) Graphical analysis of PET data applied to reversible and irreversible tracers. *Nucl Med Biol* 27:661–670
79. Lyoo CH, Ikawa M, Liow JS et al (2015) Cerebellum can serve as a pseudo-reference region in Alzheimer's disease to detect neuroinflammation with PET radioligand binding to translocator protein (TSPO). *J Nucl Med* 56:701–706
80. Schuitemaker A, van der Doef TF, Boellaard R et al (2012) Microglial activation in healthy aging. *Neurobiol Aging* 33:1067–1072
81. Owen DR, Guo Q, Kalk NJ et al (2014) Determination of [(11C)]PBR28 binding potential in vivo: a first human TSPO blocking study. *J Cereb Blood Flow Metab* 34:989–994
82. Folkersma H, Boellaard R, Yaqub M et al (2011) Widespread and prolonged increase in (R)-(11)C-PK11195 binding after traumatic brain injury. *J Nucl Med* 52:1235–1239

83. Su Z, Herholz K, Gerhard A et al (2013) [11C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. *Eur J Nucl Med Mol Imaging* 40:1406–1419
84. Schain M, Benjaminsson S, Varnäs K et al (2013) Arterial input function derived from pairwise correlations between PET-image voxels. *J Cereb Blood Flow Metab* 33:1058–1065
85. Kanegawa N, Schain M, Collste K et al (2015) Towards less invasive quantification of [11C]PBR28: image-derived and population-based input functions. XIIth: International Conference on Quantification of Brain Function with PET, Vancouver, June 27–30 2015. <http://iscbfm.org/Meetings.aspx>
86. Bilbo SD, Schwarz JM (2009) Early-life programming of later-life brain and behavior: a critical role for the immune system. *Front Behav Neurosci* 3:14
87. Jučaitė A, Cselényi Z, Arvidsson A et al (2012) Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain: a PET study in control subjects. *EJNMMI Res* 2:15
88. Park E, Gallezot J-D, Delgadillo A et al (2015) 11C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. *Eur J Nucl Med Mol Imaging* 42:1081–1092
89. Collste K, Forsberg A, Varrone A et al (2015) Test-retest reproducibility of [11C]PBR28 binding to TSPO in healthy control subjects. *Eur J Nucl Med Mol Imaging* [Epub ahead of print]
90. Lavisse S, Guillermier M, Herard A-S et al (2012) Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. *J Neurosci* 32:10809–10818
91. Tóth M, Little P, Arnberg F et al (2015) Acute neuroinflammation in a clinically relevant focal cortical ischemic stroke model in rat: longitudinal positron emission tomography and immunofluorescent tracking. *Brain Struct Funct* [Epub ahead of print]
92. Asadabadi M, Mohammadi M-R, Ghanizadeh A et al (2013) Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. *Psychopharmacology* 225:51–59
93. Sommer IE, de Witte L, Begemann M, Kahn RS (2012) Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. *J Clin Psychiatry* 73:414–419
94. Abbasi S-H, Hosseini F, Modabbernia A et al (2012) Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. *J Affect Disord* 141:308–314
95. Nitta M, Kishimoto T, Müller N et al (2013) Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. *Schizophr Bull* 39:1230–1241
96. Oya K, Kishi T, Iwata N (2014) Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. *Hum Psychopharmacol* 29:483–491
97. Laan W, Grobbee DE, Selten J-P et al (2010) Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry* 71:520–527
98. Jucaite A, Svenningsson P, Rinne JO et al (2015) Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. *Brain* 138:2687–2700
99. Deakin J, Lennox BR, Zandi MS (2014) Antibodies to the N-methyl-D-aspartate receptor and other synaptic proteins in psychosis. *Biol Psychiatry* 75:284–291
100. Raison CL (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. *JAMA Psychiatry* 70:31–41